Immunocore Q3 net loss widens to $14.22 million

Bitget2026/11/06 14:02

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Immunocore’s third-quarter 2026 net loss widened year over year to $14.22 million.
KIMMTRAK net sales fell year over year to $102.22 million.
For the first nine months of 2026, KIMMTRAK net sales rose 10% year over year to $324.83 million.
Phase 3 TEBE-AM reached its 540-patient enrollment target, with topline overall survival data expected in Q2 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunocore Holdings plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611060900PRIMZONEFULLFEED1001302014) on November 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Immunocore Q3 net loss widens to $14.22 million

You may also like

Crypto prices